A new study reveals effectiveness of a cognitive enhancer for schizophrenia treatment Blog Post

Researchers from the biotech company Iproteos and the Institute for Research in Biomedicine of Barcelona (IRB Barcelona), member of the Barcelona Institute of Science and Technology (BIST) –based at the Barcelona Science Park–  in collaboration with scientists from the Neuropsychopharmacology Research Group –belonging to the University of Basque Country /Universidad del País Vasco (UPV/EHU) and to the Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)– have published an article at European Neuropsychopharmacology, where the new procognitive drug efficacy has been demonstrated for schizophrenia treatment.

 

The Gaem Foundation has been awarded in the 2nd edition of the ‘Somos Pacientes” Awards Blog Post

The ‘Múltiple Esclerosis online’ portal (ME online) of the GAEM Foundation (Group Affected by Multiple Sclerosis), based at the Barcelona Science Park (PCB), has been one of the five projects winners in the second edition of the awards ‘Somos Pacientes‘ (We are Patients), that recognize the effort, dedication, talent and imagination of patient associations to provide assistance, services and solutions to their partners, members and society in general. 

 

SM Genomics receives the Business and Enterprise Award for Innovation 2016 Blog Post

SM Genomics, located at the Barcelona Science Park, is one of the three companies awarded in the fourth edition of the Business and Sport Awards organized by Indescat –the Catalan Sports Industry Cluster– to recognize the most outstanding projects in the field of innovation, internationalization and partnership. The awards ceremony was held at the Museu Olímpic i de l’Esport Joan Antoni Samaranch and was attended by more than 100 people from the institutional, business and sports world.  

 

Minoryx Therapeutics wins the 2016 of Senén Vilaró Prize for best innovative company Blog Post

Minoryx Therapeutics ––located at TecnoCampus Mataró-Maresme, with laboratories at the Barcelona Science Park (PCB)– has won the 2016 Senén Vilaró Prize for best innovative company, one of the four awards conferred by the Board of Trustees of the University of Barcelona and the Bosch i Gimpera Foundation (FBG). The Ramon Margalef Prize of the Board of Trustees to the best article published in a distinguished journal in the field of experimental sciences and health was for Benjamí Oller Salvia, for a  research developed during his doctoral thesis at the Institute for Research in Biomedicine (IRB Barcelona) at the PCB.

 

Upcoming Forum of the BioRegion, the summit of the Catalan healthcare and life sciences ecosystem Blog Post

To celebrate its 10th anniversary, Biocat is holding a new edition of the Forum of the BioRegion of Catalonia on 25 November at the Palau de Congressos de Catalunya in order to bring together the stakeholders in the Catalan healthcare and life sciences ecosystem and reflect on the challenges and opportunities available in this current environment of change and sectorial transformation. The latest session brought together more than 450 representatives from Catalan organizations and this year Biocat –with headquarters at the Barcelona Scientific Park – is opening the event up to international clusters.

 

IBEC and GENOMICA present NEDxA, first fruit of their collaboration Blog Post

Head of Technology Transfer Xavier Rubies, as well as representing IBEC as a research centre related to health, joined forces with representatives from Genomica to reveal NEDxA, a nano-electronic diagnostic array, at MEDICA, the world forum for medicine in Düsseldorf on 14th-17th November. The device –developed by the IBEC-Genomica Joint Unit located at IBEC’s headquarters at the Barcelona Science Park– carries out analysis to detect Human Papillomavirus (HPV) in a cheap, quick and convenient desktop device. 

 

Understanding epigenetic changes: one more step towards precision medicine Blog Post

Researchers at the Centro Nacional de Análisis Genómico (CNAG-CRG), based at the Barcelona Science Park (PCB), participate in a series of articles simultaneously published by scientists from across the International Human Epigenome Consortium (IHEC) in prestigious scientific journals. The collection of publications showcases the achievements and scientific progress made by IHEC in core areas of current epigenetic investigations.

 

Avizorex receives the EntrepreneurXXI Award in the Lifes Science category Blog Post

Today, the Caixaforum auditorium in Barcelona has hosted the 10th EmprendedorXXI Awards Ceremony, an initiative promoted by “la Caixa”, through Caixa Capital Risc, and co-awarded by the Ministry of Economy, Industry and Competitiveness, through Enisa.The biotechnology company, Avizorex Pharma, an ophthalmology biotech company with offices at Barcelona Science Park (PCB), has received the award in the Life Sciences category.

 

IRB Barcelona launches a campaign entitled “Future” to increase public awareness of biomedical research Blog Post

Today the Institute for Research in Biomedicine (IRB Barcelona) has launched a fundraising campaign called “Futur” (#IRBfutur). The campaign, which will run for two months, seeks to raise public awareness of the role that biomedical researchplays in advancing medicine, and the need to train scientists to ensure they can make the discoveries that may one day save our lives. The initiative aims to raise 25,000 euros to fund the first year of a PhD student at IRB Barcelona. The campaign is part of “Giving Tuesday”, a day devoted to charitable donations, which this year falls on Tuesday 29 November.

 

Esteve and Boehringer Ingelheim enter into an agreement to help patients with atrial fibrillation Blog Post

Esteve and Boehringer Ingelheim have reached an agreement whereby they enter into a joint promotion to share their commitment to improving the lives of patients with non-valvular atrial fibrillation (NVAF) at risk of suffering a stroke. In June 2012, Esteve has moved its Center for Drug Discovery and Preclinical Development to the Barcelona Science Park (PCB) in an attempt to shorten development time and speed up the arrival to market of innovative new drugs.